A Phase 3, Multinational, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% in Adults and Children with Primary Immunodeficiency Diseases.

Administered By

Awarded By

Contributors

Start/End

  • January 1, 2017 - January 31, 2020